<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009668</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00147018</org_study_id>
    <nct_id>NCT04009668</nct_id>
  </id_info>
  <brief_title>Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease</brief_title>
  <official_title>Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF),
      to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help
      develop individualized treatment options for future patients with TNF driven Focal segmental
      glomerulosclerosis (FSGS) or minimal change disease (MCD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine MCP1/Cr levels</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Change measured by for enzyme-linked immunosorbent assay (ELISA) testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urine TIMP1/Cr levels</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Change measured by for enzyme-linked immunosorbent assay (ELISA) testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence adverse events (AEs)</measure>
    <time_frame>Through study week 14</time_frame>
    <description>Adverse events (AEs) include abnormal clinical laboratory tests and severe AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Measured by a blood sample. Summarized descriptively, including baseline, follow-up and changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Urine Protein Creatinine Ratio (UPC)</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Measured by a blood sample. Summarized descriptively, including baseline, follow-up and changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving a nadir Urine Protein Creatinine Ratio (UPC) less than 1.5 g/g and at least a 40% reduction from baseline</measure>
    <time_frame>Week 10</time_frame>
    <description>Urine specimen</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>FSGS</condition>
  <condition>MCD</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Minimal Change Disease</condition>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab dose every other week (study weeks 0, 2, 4, 6, and 8), subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Adalimumab will be dosed based on weight</description>
    <arm_group_label>adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney biopsy confirmed Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change
             Disease (MCD) within one year of enrollment

          -  For Minimal Change Disease patients only, history of resistance to corticosteroid
             therapy

          -  Qualifying archived biopsy tissue is available for testing of gene expression
             profiling

          -  Increased urinary excretion of biomarkers of Tumor Necrosis Factor (TNF) activation
             (MCP1/Cr and/ or TIMP1/Cr) at study screening

          -  eGFR&gt;45 ml/min/1.73 m2 at screening

          -  Urine protein:creatinine ratio â‰¥1.5 g/g at screening

          -  Weight &gt;15 kg

          -  Stable therapy with angiotensin converting enzyme inhibitors, angiotensin receptor
             blockers, and oral immunosuppression agents for at least 30 days prior to enrollment

          -  Birth control use in females of child bearing potential

          -  Informed consent and assent if applicable

        Exclusion Criteria:

          -  Kidney or other solid organ or bone marrow transplant recipient

          -  Allergy or intolerance to investigational agent

          -  Secondary Focal Segmental Glomerulosclerosis (FSGS)

          -  Severe obesity

          -  Live virus vaccine in the past 3 months

          -  Malignancy, current or in the past 5 years

          -  Active local or systemic bacterial, fungal or viral infection

          -  Active or latent Hepatitis B, Hepatitis C, HIV, or tuberculosis

          -  History of demyelinating disease, e.g. Multiple Sclerosis or Guillain-Barre

          -  History of heart failure

          -  Active liver disease

          -  Systemic lupus erythematosus or ANA &gt; 1:80

          -  History of inflammatory bowel disease, e.g. ulcerative colitis or Crohns disease

          -  Cyclophosphamide in past 90 days, Rituximab in the past 180 days

          -  Pregnancy or nursing

          -  Blood white blood cell count &lt;4,500/mm3; Hg &lt;9 g/dL; Platelet count &lt;150,000/mm3 at
             enrollment. - Use of an erythropoiesis stimulating agent will not be an exclusion
             criterion.

          -  Concurrent use of interleukin-1 antagonist (Anakinra), other TNF blocking agent,
             methotrexate or abatacept

          -  Diabetes Mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debbie Gipson, MS, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Herreshoff</last_name>
    <phone>734-232-4830</phone>
    <email>umkidneystudies@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Herreshoff</last_name>
      <phone>734-232-4830</phone>
      <email>umkidneystudies@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Debbie Gipson, MS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Howard Trachtman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Sedor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Debbie Gipson, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Communicable Diseases, Medical School</investigator_title>
  </responsible_party>
  <keyword>Kidney Disease</keyword>
  <keyword>Minimal Change Disease</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This trial will follow the publication and data sharing policies of the NEPTUNE study, www.NEPTUNE-study.org
Request for ancillary studies should be submitted through the project contact and will be reviewed by the project steering committee.
After the study is completed, data will be submitted to the Nephrotic Syndrome Study Network (NEPTUNE), an NIH funded consortium. Proposals to access the data will then be submitted via the NEPTUNE Ancillary Studies program (NEPTUNE-study.org). Following closure of NEPTUNE, the trial data will convey with the NEPTUNE date to the NIH/NIDDK repository and can be accessed through this mechanism following approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>At the latest, data will be shared with the NEPTUNE Data Analysis and Coordinating Center at the time of publication of final results or 24 months after transfer of samples or raw data sets.</ipd_time_frame>
    <ipd_access_criteria>While this study is open data requests from this study will need to seek approval from the trial steering committee.
Once the data is transferred to the NEPTUNE study, all study data will become part of the aggregate NEPTUNE data and available to NEPTUNE participant sites and other requesting third parties upon request. Subsequent access to these data will be governed by the NIH Office of Rare Diseases (ORD) data sharing policies.</ipd_access_criteria>
    <ipd_url>http://neptune-study.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

